LRB

LRB is a biotechnology company focused on developing novel therapeutic solutions for neurodegenerative disorders, with a primary emphasis on Parkinson's disease. The company specializes in the discovery and development of small molecule inhibitors targeting Leucine-rich repeat kinase 2 (LRRK2), a key genetic driver of both familial and sporadic Parkinson's. By leveraging deep expertise in kinase biology and medicinal chemistry, LRB aims to create disease-modifying treatments that can slow or halt the progression of neurodegeneration. Their current pipeline is centered on optimizing lead compounds for improved brain penetration and safety profiles to support future clinical entry.